ReviewImmunity, inflammation and disease2021
Does COVID-19 contribute to development of neurological disease?
Review in Immunity, inflammation and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Association of CNS demyelination and COVID-19 infection: an updated systematic review.Journal of neurology · 2022Pooled it
- Article
- Systematic review and meta-analysis of brain neuroimaging abnormalities in COVID-19 patients and survivors.Psychoradiology · 2025Article
- Congenital anomalies and predisposition to severe COVID-19 among pediatric patients in the United States.Pediatric research · 2024Article
- Fifteen acute retrobulbar optic neuritis associated with COVID-19: A case report and review of literature.World journal of clinical cases · 2024Article
- Subdural effusion associated with COVID-19 encephalopathy: A case report.World journal of clinical cases · 2024Article
- COVID-19 restrictions promoted the newly occurring loneliness in older people - a prospective study in a memory clinic population.Frontiers in psychiatry · 2024Article
- Antiviral Activity of Graphene Oxide-Silver Nanocomposites Against Murine Betacoronavirus.International journal of nanomedicine · 2024Article
- The Hidden Impact of Covid-19 on Memory: Disclosing Subjective Complaints.Clinical neuropsychiatry · 2023Article
- Meta-Analysis of the Mechanisms Underlying COVID-19 Modulation of Parkinson's Disease.International journal of molecular sciences · 2023Article
- COVID-19 in the nervous system: physiopathology and neurological manifestations.Arquivos de neuro-psiquiatria · 2023Review
- Evolution of the newest diagnostic methods for COVID-19: a Chinese perspective.Journal of Zhejiang University. Science. B · 2023Review
- Evaluation of ABCD2 score during the development of stroke in COVID-19 patients diagnosed with transient ischemic attack in the emergency department.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2023Article
- MSC-Exosomes Carrying miRNA - Could they Enhance Tocilizumab Activity in Neuropathology of COVID-19?Stem cell reviews and reports · 2023Article
- Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies.Frontiers in microbiology · 2023Review
- Moderate Severity SARS-CoV-2 (COVID-19) Affects Ocular Vergence Indices: Eye Tracking-Based Study.Advances in experimental medicine and biology · 2023Article
- Associations between underlying diseases with COVID-19 and its symptoms among adults: a cross-sectional study.Frontiers in public health · 2023Article
- The role of Substance P in the defense line of the respiratory tract and neurological manifestations post COVID-19 infection.Frontiers in neurology · 2023Article
- Review
- Editorial: Viral infection and brain diseases.Brain research bulletin · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough coronavirus disease 2019 (COVID-19) has been associated primarily with pneumonia, recent data show that the causative agent of COVID-19, the coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can infect a large number of vital organs beyond the lungs, such as the heart, kidneys, and the brain. Thus, there is evidence showing possible retrograde transmission of the virus from the olfactory epithelium to regions of the brain stem.
methodsThis is a literature review article. The research design method is an evidence-based rapid review. The present discourse aim is first to scrutinize and assess the available literature on COVID-19 repercussion on the central nervous system (CNS). Standard literature and database searches were implemented, gathered relevant material, and extracted information was then assessed.
resultsThe angiotensin-converting enzyme 2 (ACE2) receptors being the receptor for the virus, the threat to the central nervous system is expected. Neurons and glial cells express ACE2 receptors in the CNS, and recent studies suggest that activated glial cells contribute to neuroinflammation and the devastating effects of SARS-CoV-2 infection on the CNS. The SARS-CoV-2-induced immune-mediated demyelinating disease, cerebrovascular damage, neurodegeneration, and depression are some of the neurological complications discussed here.
conclusionThis review correlates present clinical manifestations of COVID-19 patients with possible neurological consequences in the future, thus preparing healthcare providers for possible future consequences of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.